Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multinational, Randomized, Double-Blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-Stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies

Next Previous
Search
Trial Profile

A Multinational, Randomized, Double-Blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-Stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ombrabulin (Primary) ; Cisplatin
  • Indications Soft tissue sarcoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Sanofi

    • Most Recent Events

    • 05 Oct 2021 This trial has been completed in Spain (End Date: 17 Apr 2013), according to European Clinical Trials Database record.
    • 25 Jul 2019 This trial has been completed in UK - MHRA, according to European Clinical Trials Database.
    • 08 Jan 2013 Status changed from active, no longer recruiting to discontinued, according to a Sanofi media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top